Catheter developer Eximo Medical raises $1.6m

medical, medicine
medical, medicine

The Israeli company will use the funding for human clinical trials of its hybrid catheters.

Eximo Medicalhas completed its Series A financing round of $1.6 million. Medical device investment fund Accelmed led the round, with the participation of the Alfred Mann Institute at the Technion (AMIT), the Technion R&D Foundation Ltd. and a private investor.

Rehovot-based Eximo, founded in 2012, has developed a patented hybrid catheter, Cathi, which is connected to a pulsed laser system that operates at 355nm UV. The catheters tip combines laser ablation capabilities with a mechanical blunt blade. This combination will potentially improve accuracy, and enable superior precision when passing through a vessel blockage, regardless of the type of lesion or size of the vessel.

Eximos Cathi technology has the potential to optimize safety and performance expected to reduce the risk of vessel perforation. The performance of the system and its catheters in treating PAD will soon be tested in human studies in Europe and Israel during the fourth quarter of this year.

Eximos first set of catheters will offer a range of unique solutions for different blockage pathologies during atherectomy procedures in patients with Peripheral Artery Disease (PAD); a multi-billion market affecting 8-12 million Americans.

PAD is the underlying cause of around 66% of limb amputations, a life-changing operation that continues to beset patients even in the 21st century. According to US figures, around 122,000 PAD-related amputations, costing $8.3 billion in hospital costs, take place annually.

Eximo chairperson Dr. Irit Yaniv said, We have been engaged in the development of our Cathi technology for several years and are excited to have reached the stage to take its main application - the treatment of PAD patients - through its FIH clinical trials later in the year. We have every faith in the relevance of our laser system and hybrid catheters which we believe have several advantages over existing solutions in the market.

Eximos product pipeline includes solutions for Lead Extraction (LE) - the removal of defunct, malfunctioning or infected pacemaker or fibrillator leads and, at a later stage, catheters for interventional gastrointestinal procedures.

Published by Globes [online], Israel business news - - on July 29, 2015

Copyright of Globes Publisher Itonut (1983) Ltd. 2015

medical, medicine
medical, medicine
Twitter Facebook Linkedin RSS Newsletters Israel Business Conference 2018